<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46249">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504151</url>
  </required_header>
  <id_info>
    <org_study_id>1412015000</org_study_id>
    <nct_id>NCT02504151</nct_id>
  </id_info>
  <brief_title>Cannabidiol Treatment in Patients With Early Psychosis</brief_title>
  <acronym>CBD</acronym>
  <official_title>Cannabidiol Treatment in Patients With Early Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cannabidiol (CBD) is a component of herbal cannabis that is present in varying
      concentrations in cannabis extracts. CBD has been shown to produce central effects including
      hypnotic, anticonvulsive, anxiolytic and neuroprotective effects.The investigators
      hypothesize that treatment with CBD will result in: 1) Improvement evidenced by a reduction
      in scores on the Positive and Negative Syndrome Scale for Schizophrenia (PANSS), 2)
      Improvement evidenced by a reduction in the Clinical Global Impression of Severity scale
      (CGI); Secondary Hypothesis: 1) Greater improvement in functioning as measured on the
      &quot;Patient Assessment of Own Functioning Inventory: (PAOFI) and the Quality of Life Scale
      (QLS) In this 2 period cross over design, subjects will be randomized in a 1:1 ratio to
      receive either: Order 1: CBD (Period 1) followed by placebo (Period 2) or Order 2: Placebo
      (Period 1) followed by CBD (Period 2) under double-blind conditions. The 2 study periods
      will be separated by a washout of at least 2 weeks. During each period subjects will receive
      study medications (CBD [total 800mg/day] or placebo) for a period of 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Sydrome Scale</measure>
    <time_frame>Completed each time subject is seen over 10 weeks.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression of Severity scale</measure>
    <time_frame>Completed each time subject is seen over 10 weeks.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Own Functioning Inventory</measure>
    <time_frame>Completed 10 times over 10 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Scale</measure>
    <time_frame>Completed 10 times over 10 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Order 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject will receive treatment with CBD for four weeks, followed by a two week washout period, followed by four weeks of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Order 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject will receive placebo for four weeks, followed by a 2 week washout period, followed by four weeks of treatment with CBD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <arm_group_label>Order 1</arm_group_label>
    <arm_group_label>Order 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Order 1</arm_group_label>
    <arm_group_label>Order 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Primary psychotic disorder

          -  Ages 18-65 (inclusive)

        Exclusion Criteria:

          -  Current significant medical condition or other comorbidities

          -  Current substance depdendence

          -  Women who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Madison Dykins, BA</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>2526</phone_ext>
    <email>madison.dykins@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kimberlee Bielen, BA</last_name>
    <phone>203-974-7540</phone>
    <email>kimberlee.forselius@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madison Dykins, BA</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>2526</phone_ext>
      <email>madison.dykins@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Mohini Ranganathan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madison Dykins, BA</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>2526</phone_ext>
      <email>madison.dykins@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Mohini Ranganathan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>July 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mohini Ranganathan</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
